Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 28 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2015 Status changed from suspended to recruiting as reported by ClinicalTrials.gov record.